Drugs / Guanxinning Tablets (2015)
Guanxinning Tablets (2015)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07621107 | Jun 2026 → Jan 2027 expected | ST-elevation myocardial infarction, coronary microvascular disorder | Beijing Anzhen Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Guanxinning Tablets (2015) | “Guanxinning Tablets (2015), an established treatment for stable exertional angina (Grades I-II) with TCM-diagnosed heart-blood stasis syndrome, demonstrates proven safety/efficacy.” NCT07621107 ↗ |
| Known as | Guanxinning Tablet | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07621107 ↗ |
| Known as | Guanxinning Tablets (GXNT) | “Guanxinning Tablets (GXNT) used in the experimental group” NCT07621107 ↗ |
| Known as | GXNT | “Guanxinning Tablet(GXNT)” NCT07621107 ↗ |